Skip to main content
. 2016 Jun 30;9:3771–3781. doi: 10.2147/OTT.S103954

Figure 4.

Figure 4

Forest plot displaying the meta-analysis of overall survival.

Notes: (A) BEV/taxane-based triplet therapy versus BEV/taxane doublet therapy; (B) BEV/taxane therapy with the addition of a cytotoxic agent versus BEV/taxane doublet therapy; (C) BEV/taxane therapy with the addition of a biologic agent versus BEV/taxane doublet therapy.

Abbreviations: BEV, bevacizumab; HR, hazard ratio; SE, standard error; IV, inverse variance; CI, confidence interval.